A Randomized, Double-Blind, Controlled, Parallel Group, 12-Week Study to Compare the Efficacy and Safety of the Combination of Indacaterol 150 microg Once Daily With Open Label Tiotropium 18 microg Once Daily Versus Open Label Tiotropium 18 microg Once Daily in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
Latest Information Update: 07 Oct 2021
Price :
$35 *
At a glance
- Drugs Indacaterol (Primary) ; Tiotropium bromide
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms INTRUST-1
- Sponsors Novartis Pharmaceuticals
- 18 May 2011 Results presented at the 107th International Conference of the American Thoracic Society.
- 15 May 2011 Results presented at the 107th International Conference of the American Thoracic Society, according to a Novartis media release.
- 12 Feb 2011 Primary endpoint 'Forced-expiratory-volume-in-1-second' has been met, according to a Novartis media release.